Brii Biosciences Limited ( (HK:2137) ) has shared an announcement.
Brii Biosciences Limited has announced a supplemental update regarding its asset acquisition and licensing agreements related to BRII-179 and PreHevbri. The company has successfully secured more favorable terms by acquiring additional physical assets and obtaining direct control over patent rights, enhancing its operational capabilities and market position. The aggregate consideration for these transactions is set at $20.5 million, deemed fair and beneficial for shareholders.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on the development and commercialization of innovative medicines to improve public health. The company primarily operates within the pharmaceutical industry, with a specific market focus on infectious diseases and central nervous system disorders.
YTD Price Performance: 5.83%
Average Trading Volume: 1,500
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €97.53M
See more data about 2137 stock on TipRanks’ Stock Analysis page.